In the present study, ginsenoside Rg 1 (Rg 1 ), a naturally occurring drug which is hardly absorbed in gastrointestinal (GI) tract due to its high hydrophilicity and low membrane permeability, was incorporated in different compositions of water-in-oil microemulsions (MEs). And parallel artificial membrane permeability assay (PAMPA) that have been mainly utilized for the evaluation of in vitro permeability of early drug candidates was introduced in present study, as well as rat in vivo pharmacokinetics and in vitro permeability measurements, to investigate the effect of w/o ME on Rg 1 absorption. Correlation between various models as mentioned above was further performed to estimate the feasibility of PAMPA in the application of pharmaceutical preparation studies. After being administrated intraduodenally to rats, most of MEs can enhance the intestinal absorption of Rg 1 to various extents with relative bioavailability (F re ) ranging from 268 to 1270% using drug solution as control. This enhanced absorption of Rg 1 may be related to its increased membrane permeability induced by ME as exhibited in the PAMPA and rat in vitro permeability measurements. Meanwhile, rat in vivo pharmacokinetics-PAMPA correlation (r 2 ‫)2806.0؍‬ is significant (pϽ0.05) for ME, representing a potential prospect for the application of PAMPA in the study of pharmaceutical preparation in some conditions.
Being an isotropically clear and thermodynamically stable colloidal dispersions with droplet size smaller than 100 nm, microemulsion (ME) was first introduced by Hoar and Schulman in 1943. 1) Recently, there has been an increasing interests in the development of water-in-oil (w/o) ME as a novel oral drug delivery system incorporating hydrophilic biomacromolecule with poor absorption such as peptide 2, 3) and protein 4) in terms of its pharmaceutical advantages in stability, sterility, enhanced absorption and favorable curative effect.
5) The enhanced absorption offered by w/o ME may be related to the surfactant-induced membrane fluidity and thus permeability changes. 6, 7) However, the mechanism of the enhanced absorption remains still largely unknown for w/o ME on the whole. Derived from the lack of full dilution capabilities with water, w/o ME may transform into coarse emulsion, suspension or break into two much more phases accompanied with precipitation when diluted in the gastrointestinal tract, 7) which make some parameters (such as droplet size, 8) drug release, 9) refractive index, electrical conductivity and viscosity) that had been applied in evaluating other colloidal system unsuitable for reflecting the quality of w/o ME efficiently. So far, approaches applied to explore the absorption profiles of w/o ME in gastrointestinal (GI) tract were mainly confined to Caco-2 cells monolayer, animals in vitro (intestinal membrane permeability) and in vivo (pharmacokinetics) models.
Parallel artificial membrane permeability assay (PAMPA) has been developed as a non-cell-based assay that measures passive permeability of new chemical entities for screening during early stages of drug discovery since its introduction by Kansy et al. in 1998 . 10) This assay utilizes a simple phospholipid-coated filter, which has been usually prepared by impregnating a porous filter with a solution of lipids or other biological membrane constituents, to separate two compartments mimicking the passive transport of drug in GI tract. Despite absence of enzymes and transporters, PAMPA attracts considerable interests in recent years in terms of its versatility, speed, inexpensive cost, straightforward data on the passive permeation, and higher precision between laboratories comparing to cell culture studies such as Caco-2 cell monolayer that is a relatively lower throughput and labor-intensive test. And in practice, passive permeation is the major route for passage of compounds from the GI tract into the body. Therefore, PAMPA has been taken as an alternative to cellular models for the earliest absorption, distribution, metabolism, excretion (ADME) primary screening of research compounds when correlating passive permeability with in vivo oral absorption. [11] [12] [13] [14] Furthermore, some modifications in membrane compositions make PAMPA capable of predicting total passive permeability (including both transcellular and paracellular pathway) of drug across intestinal membrane 15) and passive permeability of drug through the bloodbrain barrier. 16) In addition, since no living cells are involved, PAMPA can also be performed in some non-biological circumstances such as a wide pH range of incubation solution, 17) and addition of surfactants 18) or solubilizers (including organic solvents and excipients) 19) to the incubation solution, which suggests PAMPA may be also used in the pharmaceutical formulation in some conditions. 20) Being one of main ingredient of Panax notoginseng saponins (PNS), ginsenoside Rg 1 (Rg 1 ) (molecular weightϭ 801) is a hydrophilic naturally occurring drug that is hardly absorbed in GI tract, which transports across Caco-2 cell monolayer by a passive diffusion. 21) In present study, w/o ME incorporating Rg 1 was prepared, and PAMPA measurement, rat in vitro model (everted intestinal sac), rat in vivo model (pharmacokinetics) model were utilized to evaluate the influence of ME on Rg 1 absorption. Correlation between various models as mentioned above was further performed to estimate the feasibility of PAMPA applied in the pharmaceutical preparation. , oleic acid, isopripyl myristate or 2-ethyl hexyl palmitate) with a blend of surfactants (SP, Imwitor 780 K, Imwitor 600, SQO or Span 80) and co-surfactants (EtOH, PEG 400 or propylene glycol) (surfactant/co-surfactant ratio: 0.5, 1.0, 1.5 or 2.0) until a transparent w/o ME was obtained. The area enclosed by the w/o ME existence field was analyzed among different compositions to obtain appropriate formulation.
Evaluation of Intestinal Absorption of
Determination of Rg 1 by HPLC High performance liquid chromatography (HPLC) was carried out using a YMC ODS C 18 column (5 mm, 4.2 i.d.ϫ150 mm, Japan) with a liquid chromatograph (LC-10AT, Shimadzu, Japan) and a UV-VIS detector (SPD-101, Shimadzu, Japan) at 203 nm. A mobile phase with the speed of 1 ml/min consisting of acetonitrile : 20 mM NaH 2 PO 4 (25 : 75, v/v) was used for chromatographic resolution.
Solid phase extraction (SPE) cartridges (strata-X, Phenomenex) were conditioned under vacuum with 1 ml of methanol and 1 ml of water. Then, 200 ml of plasma samples were mixed with 4 ml of 85% (v/v) phosphoric acid, and centrifuged at 9000 g for 10 min. One hundred microliters of supernatants were applied to SPE cartridges and drawn through under low vacuum. Washed cartridges with 1 ml of 5% (v/v) methanol aqueous solution, then elute them with 1 ml of methanol and evaporated to dryness under the stream of nitrogen at 40°C. Finally, reconstituted the residues in 100 ml mobile phase and 10 ml was injected into HPLC.
Bioavailability Studies after Intraduodenal Administration in Rat Male Sprague-Dawley rats weighing 250-300 g were anesthetized lightly with diethyl ether after a 20 h fasting, and then drug solution (Rg 1 concentration 41.04 mg/ ml) and different composition of w/o MEs were administrated intraduodenally (id) to the rats at a dose volume of 4 ml/kg (dose, see Table 2 ). After the small surgery on the duodenum in the rats, muscle and skin of the main incision were sutured carefully. Blood samples were collected from caudal vein at 0.25, 0.5, 0.75, 1, 2, 4, 6, 8, and 12 h after id administration, and the rats have already been postanaesthetic recovery at that time. Plasma samples were obtained by centrifugation at 4000 g for 10 min after the blood collection and the plasma concentration of Rg 1 was determined by HPLC. Pharmacokinetic behavior of Rg 1 after intravenous (iv) administration (13.68 mg/kg) through caudal vein in rats was also conducted to evaluate the absolute bioavailability of both drug solution and microemulsion after id administration.
Model-independent methods based on the theory of statistical moments were used to characterize the pharmacokinetics of Rg 1 after id administration of solution or w/o ME. AUC (area under the plasma concentration versus time curve) and MRT (mean residence time) were calculated by numerical integration under the trapezoidal rule as described. 22) Because this was observed over a limited period of time, extrapolation to an infinity time was carried out using a monoexponential equation. The absolute bioavailability (F) and relative bioavailability (F re ) of Rg 1 was calculated through dividing AUC id /X 0,id by the AUC iv /X 0,iv , and dividing AUC ME /Dose ME by the AUC solution /Dose solution respectively.
Transport of Rg 1 across Everted Intestinal Sacs Everted intestinal sac experiments were performed according to the method described by Deshmukh with some modification. 23) Male Sprague-Dawley rats weighing 220-250 g were fasted overnight with free access to water until the rats were anaesthetized with urethane. Then, a middle abdominal incision was made and jejunum was taken quickly. After the underlying mesenterium was removed, the jejunum was flushed with ice-cold Tyrode's solution to remove intestinal contents. The jejunum was gently stretched and cut into segments (10 cm long each). Each of the sacs was carefully everted with a glass rod. One end was ligated, the other end was ligated with a conical rubber stopper that housed one port for removal and addition of the serosal fluid, and another port for continuous supply for 5% CO 2 and 95% O 2 throughout the experiment.
After being filled with 2 ml Tyrode's solution as serosal fluid (inner compartment), the sacs were incubated in 25 ml mucosal fluid (outer compartment) that was obtained by diluting w/o MEs with Tyrode's solution (1→20, v/v) (D-ME) at 37°C in a water bath. Five hundred microliters of the serosal fluid inside the sac was taken at predetermined times (15 min, 30 min, 45 min, 60 min) followed by immediate replacement with fresh Tyrode's solution of the same volume (500 ml). All samples were reserved at Ϫ20°C until analysis by HPLC. The viability of the intestinal membrane during the course of the experiments was monitored by measuring the activity of lactic acid dehydrogenase (LDH) released from the intestinal mucosa. Enhanced rate (ER) of Rg 1 transport across rat intestine was calculated as followed equation to evaluate the influence of the ME on Rg 1 absorption.
Where C 60 min, control and C 60 min, ME are the concentration of Rg 1 in serosal fluid at 60 min when drug solution (control) and D-MEs were used as mucosal fluids respectively. C 0 min, control and C 0 min, ME are the initial concentration of Rg 1 in mucosal fluids (drug solution or D-MEs).
PAMPA Method The following protocol was applied to measuring P e values. A 10% solution (w/v) of egg lecithin (phosphatidyl choline Ͼ98%, lipoid) in dodecane 10) was obtained as artificial membrane solution by ultrasound. Each donor filtration plate well was then impregnated with 10 ml of this solution carefully, avoid touching with pipet tip in case of damage of the membrane. Immediately after the application of the artificial membrane, each well of donor plate was introduced 150 ml of phosphate buffer (pH 7.4) containing Rg 1 at 11 mg/ml, or MEs which was diluted with phosphate buffer (pH 7.4) (D-ME) or not (ME) (Rg 1 concentration in MEs refers to Table 1 ). Then the drug-filled donor plate was placed into the acceptor plate that had been prefilled with phosphate buffer (pHϭ7.4, 300 ml) as acceptor solution, making sure the underside of the membrane was in contact with the buffer in all wells. After plate lid was replaced, the resulting assembled donor-acceptor plates were placed in a sealed container with wet paper towels to avoid evaporation, and incubated at room temperature for 2 h under constant light shaking (50 rpm), following which Rg 1 concentration in the acceptor solutions were determined by HPLC. Permeability of Rg 1 transporting across the artificial membrane was calculated according to the equation:
Where P e is the effective permeability coefficient (cm · s , t is incubation time for the assay, C acceptor is the concentration of the compound in the acceptor compartment at the completion of the assay, and C equilibrium is the concentration of compound at theoretical equilibrium.
Statistical Analysis Values are expressed as meanϮS.D. The difference among mean values was analyzed with twotailed Student's t-test and comparisons among more than three groups were performed by using one-way ANOVA. pϽ0.05 was considered to be significant.
RESULTS AND DISCUSSION

Microemulsion Formulations
In preparation of w/o ME, much more drug solution could be dissolved in most kinds of oils as mentioned in the text when SP was used as main surfactant than that was dissolved in oils when Imwitor 780 K, Imwitor 600, Span 80, and SQO were used as main surfactants. And considering favourable safety and biocompatibility offered by SP, it was selected and further mixed with EtOH (a co-surfactant) as the surfactant/co-surfactant at a ratio of 1/1 (w/w) in MEs. Thus, ten MEs were developed by titrating a mixture of drug solution and oils with SP/EtOH (1/1) until a clear and transparent appearance was obtained. The composition of MEs was showed in Table 1 without lower Rg 1 concentration than 10 mg/ml. Otherwise, difficulties in administrating intraduodenally to rats and performing PAMPA precisely for ME could be brought when Maisine 35-1 ® was used as oil phase due to its relatively high melting point causing solidification of the w/o ME at room temperature after addition of the SP/EtOH. SQO was then substituted for SP/EtOH in the ME to prepare a liquid w/o ME using Maisine 35-1 ® as oil phase. Droplet size of MEs as presented in Table 1 was below 100 nm (e.g. 17.8Ϯ1.7 nm for ME I).
Pharmacokinetics and Everted Intestinal Sac Studies Pharmacokinetic behavior of w/o ME was experimented in rats after id administration. Although absolute bioavailability (F) of various w/o MEs was lower than 20%, most of them can enhance intestinal absorption of Rg 1 to various extents with relative bioavailability (F re ) ranging from 268 to 1270% in comparison to drug solution (Table 2) , as well as promote the permeation of Rg 1 across intestinal membrane as shown in the everted intestinal sac studies (Table 3 ). Before rat everted sac studies, it is essential to dilute w/o MEs with Tyrode's solution because of its incompatibility of continuous oil phase with biological membrane. Low extent of dilution for w/o ME in mucosal fluid may induce the damage to intestinal membrane due to a relatively high concentration of surfactants in mucosal fluid, whereas high extent of dilution for w/o ME leads to the low concentration of Rg 1 in serosal fluid, and thus resulting in the inability to be quantitated. Therefore, diluted w/o ME (D-ME) (1→20, v/v) were used in the rat everted intestinal sac studies after some tries, and no evident damage to intestinal membrane was observed in 1 h during experiments as demonstrated by the determination of LDH. Not all the w/o MEs represent coincident and enhanced effects on Rg 1 absorption in both rat in vivo and in vitro models. Particularly, ME II and ME VI could increase Rg 1 bioavailability to 10 times higher than that of control (solution). In contrast, no pharmacokinetic parameters could be obtained for ME IV and ME X since the Rg 1 concentration in plasma is too low to be determined exactly. This disparate effect on the drug absorption among various ME formulations may be related to the difference of drug content loaded in MEs on the one hand, and on the other hand, composition of MEs could contribute to a large great extent. Except surfactants that could interact with intestinal mucosa membrane causing increase of permeability of drug across intestinal membrane, some fatty acids and glycerides such as IPM, Miglyol 812, oleic acid and other monoglycerides may also enhance drug absorption by penetrating into the intestinal membrane to induce disorder of the membrane and thus causing the increase of membrane fluidity, 24) which is also observed by us that w/o MEs prepared in present study could increase the membrane fluidity of liposome as a model of the biological membrane using DPH (1,6-dipheny1-1,3,5-hexatrene) as a fluorescence probe that is incorporated in the inner apolar core of the membrane (data not shown). Meanwhile, some fatty glycerides were reported to promote the paracellular diffusion of drug through intracellular regulation of tight junction. 25) Additionally, in an attempt to explore relationship between lipid components and drug absorption, solubility and dissolution of the lipophilic drug could be improved significantly by in vitro digestion products of some medium-long chain triglycerides, [26] [27] [28] [29] which could be also demonstrated by the fact that much more cyclosporine oils (Miglyol 812 or olive oil) that had been digested in vitro could be absorbed in GI tract of rat with bile duct ligated than that could be absorbed without in vitro digestion. 30) However, the lipid digestion may have no significant influence on the solubility and dissolution of Rg 1 because of its potent hydrophilicity, and our preliminary experiments showed that no evident change depending upon the in vitro digestion was observed for the solubility of the Rg 1 incorporated in MEs.
PAMPA Studies and Correlation In present study, egg lecithin dissolved in dodecane was used as model membrane barrier in the PAMPA method to mimic the high presence of phosphatidylcholine in mammalian membranes. 20) Because lack of transporter-and pore-mediated permeability, PAMPA may underestimate the permeation value of some compounds which transport across membrane partly by transporter and/or paracellular routes. Thus, as an excellent bio-mimetic model, PAMPA only estimates the ability of molecules to permeate membrane by transcellular passive diffusion. 31) Since Rg 1 is known to transport across Caco-2 cell monolayer by a passive permeation, 21) comparative studies on correlation of PAMPA (P e ) with rat in vivo pharmacokinetics (F re ) and rat in vitro permeability (ER) were performed to explore the feasibility of PAMPA applied in the screen of pharmaceutical preparation studies. Because the concentration of Rg 1 in plasma for ME IV and ME X is too low to be determined, the corresponding F re for both of them was then set to 
(nϭ3).
ERϭ(C ME, 60min /C ME, 0 min )/(C control, 60 min /C control, 0 min ). * Significanly different from control (pϽ0.05).
be 0 value to carry out the subsequent correlation studies.
A dilution of w/o ME by gastrointestinal fluid in GI tract is unavoidable, thus P e values of D-MEs were first investigated. Hitherto, mechanisms of enhanced oral absorption for lipophilic drug offered by o/w ME have been comparatively clarified, such as improved solubility and dissolution, [26] [27] [28] [29] increased intestinal membrane permeability, 32) or accelerated transport of lipophilic drug through the routes of lymph. 33) However, it is still largely unclear for w/o ME, one of the primary mechanisms is considered to be releated to its increased intestinal membrane permeability of drug, the medium chain length fatty acid lipid components and other bioenhancers such as phosphatidylcholine (PC) that are commonly consisted in the w/o MEs have been shown to enhance transmemebrane passage of drug across the digestive tract, thus improving the bioavailability. 24, 34) It was further confirmed in the present study as shown in Table 3 , P e (D-MEs) are mostly higher than that of drug solution (Rg 1 concentration 11 mg/ml) (8.61Ϯ2.26ϫ10 Ϫ8 cm/s), as well as rat in vitro permeability model (everted intestinal sac), suggesting the increased membrane permeability of Rg 1 offered by w/o ME. Otherwise, an additional process for drug released from the inner aqueous phase to the PAMPA membrane decreased the P e values of most of w/o MEs in comparison to that of both D-MEs and solution (Table 3) . However, the correlation of P e -ER, P e -F re and ER-F re are not significant (pϾ0.05) for D-MEs, which may be attributed to the deviation in the data of both P e (D-ME) and ER originating from the phase inversion of w/o MEs after being diluted with buffer solution. For instance, the lipids precipitated from D-MEs after dilution may adhere to the membrane surface of the PAMPA or the intestinal mucosa of the rats everted intestinal sac, thus interfering with the accuracy and reproducibility of the results. On the other hand, a relatively large volume of w/o MEs (4 ml/kg) was dosed directly into the duodenum of rats thereby limiting the chances of phase inversion and magnifying absorption enhancing properties of the undiluted w/o ME, which might also result in the insignificant correlation between P e , ER and F re for the diluted microemulsion (D-ME). In contrast, undiluted w/o microemulsion (ME) that is homogeneous and isotropical systems may also reflect the effects of w/o MEs on drug permeability to some extent, and a better, significant correlation for w/o MEs could be observed between P e and F re (r 2 ϭ0.6082) (pϽ0.05), suggesting the potential prospect for the application of PAMPA in the pharmaceutical research in some conditions, especially for the study of homogeneous and isotropical delivery system. Further studies is required to investigate the effect of administrated volume on the intestinal absorption and correlation between P e and F re for D-ME.
In conclusion, w/o microemulsion (ME) can enhance the intestinal absorption of a hydrophilic drug (Rg 1 ) after id administration to rats, which may be due to the increased membrane permeability provided by w/o MEs as shown in PAMPA and rat everted intestinal sac studies. PAMPA may be introduced in the study of the pharmaceutical preparation to evaluate the membrane permeability in some conditions.
